Skip to main content
Top
Published in: Immunity & Ageing 1/2011

Open Access 01-12-2011 | Review

The "Alzheimer's disease signature": potential perspectives for novel biomarkers

Authors: Sergio Davinelli, Mariano Intrieri, Claudio Russo, Alfonso Di Costanzo, Davide Zella, Paolo Bosco, Giovanni Scapagnini

Published in: Immunity & Ageing | Issue 1/2011

Login to get access

Abstract

Alzheimer's disease is a progressive and neurodegenerative disorder which involves multiple molecular mechanisms. Intense research during the last years has accumulated a large body of data and the search for sensitive and specific biomarkers has undergone a rapid evolution. However, the diagnosis remains problematic and the current tests do not accurately detect the process leading to neurodegeneration. Biomarkers discovery and validation are considered the key aspects to support clinical diagnosis and provide discriminatory power between different stages of the disorder. A considerable challenge is to integrate different types of data from new potent approach to reach a common interpretation and replicate the findings across studies and populations. Furthermore, long-term clinical follow-up and combined analysis of several biomarkers are among the most promising perspectives to diagnose and manage the disease. The present review will focus on the recent published data providing an updated overview of the main achievements in the genetic and biochemical research of the Alzheimer's disease. We also discuss the latest and most significant results that will help to define a specific disease signature whose validity might be clinically relevant for future AD diagnosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alzheimer's Association: 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 2010, 6: 158-94.CrossRef Alzheimer's Association: 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 2010, 6: 158-94.CrossRef
2.
go back to reference Ho L, Fivecoat H, Wang J, Pasinetti GM: Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. Exp Gerontol. 2010, 45: 15-22. 10.1016/j.exger.2009.09.007.PubMedCentralCrossRefPubMed Ho L, Fivecoat H, Wang J, Pasinetti GM: Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. Exp Gerontol. 2010, 45: 15-22. 10.1016/j.exger.2009.09.007.PubMedCentralCrossRefPubMed
3.
go back to reference Grimes DA, Schulz KF: Uses and abuses of screening tests. Lancet. 2002, 359: 881-4. 10.1016/S0140-6736(02)07948-5.CrossRefPubMed Grimes DA, Schulz KF: Uses and abuses of screening tests. Lancet. 2002, 359: 881-4. 10.1016/S0140-6736(02)07948-5.CrossRefPubMed
4.
go back to reference Querfurth HW, LaFerla FM: Alzheimer's disease. N Engl J Med. 2010, 362: 329-44. 10.1056/NEJMra0909142.CrossRefPubMed Querfurth HW, LaFerla FM: Alzheimer's disease. N Engl J Med. 2010, 362: 329-44. 10.1056/NEJMra0909142.CrossRefPubMed
5.
go back to reference Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT: Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 2009, 32: 150-9. 10.1016/j.tins.2008.11.007.CrossRefPubMed Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT: Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 2009, 32: 150-9. 10.1016/j.tins.2008.11.007.CrossRefPubMed
6.
go back to reference Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992, 256: 184-185. 10.1126/science.1566067.CrossRefPubMed Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992, 256: 184-185. 10.1126/science.1566067.CrossRefPubMed
7.
go back to reference Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet. 2006, 368: 387-403. 10.1016/S0140-6736(06)69113-7.CrossRefPubMed Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet. 2006, 368: 387-403. 10.1016/S0140-6736(06)69113-7.CrossRefPubMed
8.
go back to reference Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008, 65: 1102-1107. 10.1001/archneur.65.8.1102.CrossRefPubMed Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008, 65: 1102-1107. 10.1001/archneur.65.8.1102.CrossRefPubMed
9.
go back to reference Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K: Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry. 2007, 64: 718-726. 10.1001/archpsyc.64.6.718.CrossRefPubMed Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K: Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry. 2007, 64: 718-726. 10.1001/archpsyc.64.6.718.CrossRefPubMed
11.
go back to reference Pimplikar SW: Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol. 2009, 41: 1261-68. 10.1016/j.biocel.2008.12.015.PubMedCentralCrossRefPubMed Pimplikar SW: Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol. 2009, 41: 1261-68. 10.1016/j.biocel.2008.12.015.PubMedCentralCrossRefPubMed
12.
go back to reference Zetterberg H, Blennow K, Hanse E: Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp Gerontol. 2010, 45: 23-9. 10.1016/j.exger.2009.08.002.CrossRefPubMed Zetterberg H, Blennow K, Hanse E: Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp Gerontol. 2010, 45: 23-9. 10.1016/j.exger.2009.08.002.CrossRefPubMed
13.
go back to reference Lescuyer P, Allard L, Zimmermann-Ivol CG, Burgess JA, Hughes-Frutiger S, Burkhard PR: Identification of post-mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration. Proteomics. 2004, 4: 2234-2241. 10.1002/pmic.200300822.CrossRefPubMed Lescuyer P, Allard L, Zimmermann-Ivol CG, Burgess JA, Hughes-Frutiger S, Burkhard PR: Identification of post-mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration. Proteomics. 2004, 4: 2234-2241. 10.1002/pmic.200300822.CrossRefPubMed
14.
go back to reference Finehout EJ, Franck Z, Relkin N, Lee KH: Proteomic analysis of cerebrospinal fluid changes related to postmortem interval. Clin Chem. 2006, 52: 1906-1913. 10.1373/clinchem.2006.070508.CrossRefPubMed Finehout EJ, Franck Z, Relkin N, Lee KH: Proteomic analysis of cerebrospinal fluid changes related to postmortem interval. Clin Chem. 2006, 52: 1906-1913. 10.1373/clinchem.2006.070508.CrossRefPubMed
15.
go back to reference Hernandez F, Avila J: Tauopathies. Cell Mol Life Sci. 2007, 64: 2219-2233. 10.1007/s00018-007-7220-x.CrossRefPubMed Hernandez F, Avila J: Tauopathies. Cell Mol Life Sci. 2007, 64: 2219-2233. 10.1007/s00018-007-7220-x.CrossRefPubMed
16.
go back to reference Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A: Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem. 2007, 282: 23645-23654. 10.1074/jbc.M703269200.CrossRefPubMed Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A: Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem. 2007, 282: 23645-23654. 10.1074/jbc.M703269200.CrossRefPubMed
17.
go back to reference Meraz-Rios MA, Lira-De Leon KI, Campos-Pena V, De Anda-Hernandez MA, Mena-Lopez R: Tau oligomers and aggregation in Alzheimer's disease. J Neurochem. 2010, 112: 1353-67. 10.1111/j.1471-4159.2009.06511.x.CrossRefPubMed Meraz-Rios MA, Lira-De Leon KI, Campos-Pena V, De Anda-Hernandez MA, Mena-Lopez R: Tau oligomers and aggregation in Alzheimer's disease. J Neurochem. 2010, 112: 1353-67. 10.1111/j.1471-4159.2009.06511.x.CrossRefPubMed
18.
go back to reference Small SA, Duff K: Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron. 2008, 60: 534-42. 10.1016/j.neuron.2008.11.007.PubMedCentralCrossRefPubMed Small SA, Duff K: Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron. 2008, 60: 534-42. 10.1016/j.neuron.2008.11.007.PubMedCentralCrossRefPubMed
19.
go back to reference Takashima A: Amyloid-beta, tau, and dementia. J Alzheimers Dis. 2009, 17: 729-36.PubMed Takashima A: Amyloid-beta, tau, and dementia. J Alzheimers Dis. 2009, 17: 729-36.PubMed
20.
go back to reference Hardy J: The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem. 2009, 110: 1129-1134. 10.1111/j.1471-4159.2009.06181.x.CrossRefPubMed Hardy J: The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem. 2009, 110: 1129-1134. 10.1111/j.1471-4159.2009.06181.x.CrossRefPubMed
21.
go back to reference Devi L, Anandatheerthavarada HK: Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochim Biophys Acta. 2010, 1802: 11-19.PubMedCentralCrossRefPubMed Devi L, Anandatheerthavarada HK: Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochim Biophys Acta. 2010, 1802: 11-19.PubMedCentralCrossRefPubMed
22.
go back to reference Mancuso C, Scapagnini G, Currò D, Giuffrida Stella AM, De Marco C, Butterfield DA, Calabrese V: Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci. 2007, 12: 1107-1123. 10.2741/2130.CrossRefPubMed Mancuso C, Scapagnini G, Currò D, Giuffrida Stella AM, De Marco C, Butterfield DA, Calabrese V: Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci. 2007, 12: 1107-1123. 10.2741/2130.CrossRefPubMed
23.
go back to reference Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A: Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006, 63: 168-174. 10.1001/archpsyc.63.2.168.CrossRefPubMed Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A: Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006, 63: 168-174. 10.1001/archpsyc.63.2.168.CrossRefPubMed
24.
25.
go back to reference Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H: The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet. 2007, 16: 15-23.CrossRefPubMed Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H: The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet. 2007, 16: 15-23.CrossRefPubMed
27.
go back to reference Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993, 261: 921-923. 10.1126/science.8346443.CrossRefPubMed Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993, 261: 921-923. 10.1126/science.8346443.CrossRefPubMed
28.
go back to reference Wolk DA, Dickerson BC, Alzheimer's Disease Neuroimaging Initiative: Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer disease. Proc Natl Acad Sci USA. 2010, 107: 10256-10261. 10.1073/pnas.1001412107.PubMedCentralCrossRefPubMed Wolk DA, Dickerson BC, Alzheimer's Disease Neuroimaging Initiative: Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer disease. Proc Natl Acad Sci USA. 2010, 107: 10256-10261. 10.1073/pnas.1001412107.PubMedCentralCrossRefPubMed
29.
go back to reference Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genet. 2009, 41: 1088-93. 10.1038/ng.440.PubMedCentralCrossRefPubMed Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genet. 2009, 41: 1088-93. 10.1038/ng.440.PubMedCentralCrossRefPubMed
30.
go back to reference DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR: Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2002, 99: 10843-10848. 10.1073/pnas.162228299.PubMedCentralCrossRefPubMed DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR: Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2002, 99: 10843-10848. 10.1073/pnas.162228299.PubMedCentralCrossRefPubMed
31.
go back to reference DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW: ApoE and clusterin cooperatively suppress Abeta levels and deposition: Evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004, 41: 193-202. 10.1016/S0896-6273(03)00850-X.CrossRefPubMed DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW: ApoE and clusterin cooperatively suppress Abeta levels and deposition: Evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004, 41: 193-202. 10.1016/S0896-6273(03)00850-X.CrossRefPubMed
32.
go back to reference Tebar F, Bohlander SK, Sorkin A: Clathrin assembly lymphoid myeloid leukemia (CALM) protein: Localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell. 1999, 10: 2687-2702.PubMedCentralCrossRefPubMed Tebar F, Bohlander SK, Sorkin A: Clathrin assembly lymphoid myeloid leukemia (CALM) protein: Localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell. 1999, 10: 2687-2702.PubMedCentralCrossRefPubMed
33.
go back to reference Harel A, Wu F, Mattson MP, Morris CM, Yao PJ: Evidence for CALM in directing VAMP2 trafficking. Traffic. 2008, 9: 417-429. 10.1111/j.1600-0854.2007.00694.x.CrossRefPubMed Harel A, Wu F, Mattson MP, Morris CM, Yao PJ: Evidence for CALM in directing VAMP2 trafficking. Traffic. 2008, 9: 417-429. 10.1111/j.1600-0854.2007.00694.x.CrossRefPubMed
34.
go back to reference Yao PJ, Petralia RS, Bushlin I, Wang Y, Furukawa K: Synaptic distribution of the endocytic accessory proteins AP180 and CALM. J Comp Neurol. 2005, 481: 58-69. 10.1002/cne.20362.CrossRefPubMed Yao PJ, Petralia RS, Bushlin I, Wang Y, Furukawa K: Synaptic distribution of the endocytic accessory proteins AP180 and CALM. J Comp Neurol. 2005, 481: 58-69. 10.1002/cne.20362.CrossRefPubMed
35.
go back to reference Nizzari M, Venezia V, Repetto E, Caorsi V, Magrassi R, Gagliani MC: Amyloid precursor protein and Presenilin1 interact with the adaptor GRB2 and modulate ERK 1,2 signaling. J Biol Chem. 2007, 282: 13833-13844. 10.1074/jbc.M610146200.CrossRefPubMed Nizzari M, Venezia V, Repetto E, Caorsi V, Magrassi R, Gagliani MC: Amyloid precursor protein and Presenilin1 interact with the adaptor GRB2 and modulate ERK 1,2 signaling. J Biol Chem. 2007, 282: 13833-13844. 10.1074/jbc.M610146200.CrossRefPubMed
36.
go back to reference Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL: GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron. 2007, 54: 713-720. 10.1016/j.neuron.2007.05.022.PubMedCentralCrossRefPubMed Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL: GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron. 2007, 54: 713-720. 10.1016/j.neuron.2007.05.022.PubMedCentralCrossRefPubMed
37.
go back to reference Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A: Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet. 2010, 19: 3295-3301. 10.1093/hmg/ddq221.PubMedCentralCrossRefPubMed Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A: Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet. 2010, 19: 3295-3301. 10.1093/hmg/ddq221.PubMedCentralCrossRefPubMed
38.
go back to reference Khera R, Das N: Complement Receptor 1: Disease associations and therapeutic implications. Mol Immunol. 2009, 46: 761-772. 10.1016/j.molimm.2008.09.026.CrossRefPubMed Khera R, Das N: Complement Receptor 1: Disease associations and therapeutic implications. Mol Immunol. 2009, 46: 761-772. 10.1016/j.molimm.2008.09.026.CrossRefPubMed
39.
go back to reference Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M: Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010, 303: 1832-1840. 10.1001/jama.2010.574.PubMedCentralCrossRefPubMed Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M: Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010, 303: 1832-1840. 10.1001/jama.2010.574.PubMedCentralCrossRefPubMed
40.
go back to reference Pant S, Sharma M, Patel K, Caplan S, Carr CM, Grant BD: AMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling. Nat Cell Biol. 2009, 11: 1399-1410. 10.1038/ncb1986.PubMedCentralCrossRefPubMed Pant S, Sharma M, Patel K, Caplan S, Carr CM, Grant BD: AMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling. Nat Cell Biol. 2009, 11: 1399-1410. 10.1038/ncb1986.PubMedCentralCrossRefPubMed
41.
go back to reference Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F: Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol. 2010, 67: 961-964. 10.1001/archneurol.2010.147.PubMedCentralCrossRefPubMed Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F: Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol. 2010, 67: 961-964. 10.1001/archneurol.2010.147.PubMedCentralCrossRefPubMed
42.
go back to reference Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM: Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011, 43: 429-35. 10.1038/ng.803.PubMedCentralCrossRefPubMed Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM: Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011, 43: 429-35. 10.1038/ng.803.PubMedCentralCrossRefPubMed
43.
go back to reference Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J: Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011, 43: 436-41. 10.1038/ng.801.PubMedCentralCrossRefPubMed Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J: Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011, 43: 436-41. 10.1038/ng.801.PubMedCentralCrossRefPubMed
44.
go back to reference Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmüller F: Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology. 2000, 55: 480-483.CrossRefPubMed Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmüller F: Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology. 2000, 55: 480-483.CrossRefPubMed
45.
go back to reference Voineskos AN, Lerch JP, Felsky D, Shaikh S, Rajji TK, Miranda D: The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease. Arch Gen Psychiatry. 2011, 68: 198-206. 10.1001/archgenpsychiatry.2010.194.CrossRefPubMed Voineskos AN, Lerch JP, Felsky D, Shaikh S, Rajji TK, Miranda D: The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease. Arch Gen Psychiatry. 2011, 68: 198-206. 10.1001/archgenpsychiatry.2010.194.CrossRefPubMed
46.
go back to reference Reitz C, Tokuhiro S, Clark LN, Conrad C, Vonsattel JP, Hazrati LN: SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann Neurol. 2011, 69: 47-64. 10.1002/ana.22308.PubMedCentralCrossRefPubMed Reitz C, Tokuhiro S, Clark LN, Conrad C, Vonsattel JP, Hazrati LN: SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann Neurol. 2011, 69: 47-64. 10.1002/ana.22308.PubMedCentralCrossRefPubMed
47.
go back to reference Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T: Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology. 2011, 76: 69-79. 10.1212/WNL.0b013e318204a397.PubMedCentralCrossRefPubMed Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T: Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology. 2011, 76: 69-79. 10.1212/WNL.0b013e318204a397.PubMedCentralCrossRefPubMed
48.
go back to reference Di Bona D, Candore G, Franceschi C, Licastro F, Colonna-Romano G, Cammà C: Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease. Brain Res Rev. 2009, 61: 60-68. 10.1016/j.brainresrev.2009.05.001.CrossRefPubMed Di Bona D, Candore G, Franceschi C, Licastro F, Colonna-Romano G, Cammà C: Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease. Brain Res Rev. 2009, 61: 60-68. 10.1016/j.brainresrev.2009.05.001.CrossRefPubMed
49.
go back to reference Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009, 65: 403-413. 10.1002/ana.21610.PubMedCentralCrossRefPubMed Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009, 65: 403-413. 10.1002/ana.21610.PubMedCentralCrossRefPubMed
50.
go back to reference Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007, 13: 1359-1362. 10.1038/nm1653.CrossRefPubMed Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007, 13: 1359-1362. 10.1038/nm1653.CrossRefPubMed
51.
go back to reference Qin W, Ho L, Wang J, Peskind E, Pasinetti GM: S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS One. 2009, 4: e4183-10.1371/journal.pone.0004183.PubMedCentralCrossRefPubMed Qin W, Ho L, Wang J, Peskind E, Pasinetti GM: S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS One. 2009, 4: e4183-10.1371/journal.pone.0004183.PubMedCentralCrossRefPubMed
52.
go back to reference Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S: Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 2004, 3: 1154-69. 10.1074/mcp.M400129-MCP200.CrossRefPubMed Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S: Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 2004, 3: 1154-69. 10.1074/mcp.M400129-MCP200.CrossRefPubMed
53.
go back to reference Thompson A, Schäfer J, Kuhn K, Kienle S, Schwarz J, Schmidt G: Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem. 2003, 75: 1895-904. 10.1021/ac0262560.CrossRefPubMed Thompson A, Schäfer J, Kuhn K, Kienle S, Schwarz J, Schmidt G: Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem. 2003, 75: 1895-904. 10.1021/ac0262560.CrossRefPubMed
54.
go back to reference Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R: Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999, 17: 994-999. 10.1038/13690.CrossRefPubMed Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R: Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999, 17: 994-999. 10.1038/13690.CrossRefPubMed
55.
go back to reference Schmidt A, Kellermann J, Lottspeich F: novel strategy for quantitative proteomics using isotope-coded protein labels. A Proteomics. 2005, 5: 4-15. 10.1002/pmic.200400873.CrossRefPubMed Schmidt A, Kellermann J, Lottspeich F: novel strategy for quantitative proteomics using isotope-coded protein labels. A Proteomics. 2005, 5: 4-15. 10.1002/pmic.200400873.CrossRefPubMed
56.
go back to reference Vemuri P, Gunter JL, Senjem ML, Whitwell JL, Kantarci K, Knopman DS: Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage. 2008, 39: 1186-97. 10.1016/j.neuroimage.2007.09.073.PubMedCentralCrossRefPubMed Vemuri P, Gunter JL, Senjem ML, Whitwell JL, Kantarci K, Knopman DS: Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage. 2008, 39: 1186-97. 10.1016/j.neuroimage.2007.09.073.PubMedCentralCrossRefPubMed
57.
go back to reference Hua X, Leow AD, Parikshak N, Lee S, Chiang MC, Toga AW: Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage. 2008, 43: 458-69. 10.1016/j.neuroimage.2008.07.013.PubMedCentralCrossRefPubMed Hua X, Leow AD, Parikshak N, Lee S, Chiang MC, Toga AW: Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage. 2008, 43: 458-69. 10.1016/j.neuroimage.2008.07.013.PubMedCentralCrossRefPubMed
58.
59.
go back to reference Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW: Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. Journal of Neural Transmission. 2009, 116: 203-12. 10.1007/s00702-008-0177-6.CrossRefPubMed Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW: Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. Journal of Neural Transmission. 2009, 116: 203-12. 10.1007/s00702-008-0177-6.CrossRefPubMed
60.
go back to reference Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM: Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 2010, 119: 669-78. 10.1007/s00401-010-0667-0.PubMedCentralCrossRefPubMed Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM: Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 2010, 119: 669-78. 10.1007/s00401-010-0667-0.PubMedCentralCrossRefPubMed
61.
go back to reference Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC: Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010, 6: 230-238. 10.1016/j.jalz.2010.03.008.PubMedCentralCrossRefPubMed Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC: Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010, 6: 230-238. 10.1016/j.jalz.2010.03.008.PubMedCentralCrossRefPubMed
62.
go back to reference Mattsson N, Zetterberg H: Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications. Biomark Med. 2009, 3: 735-737. 10.2217/bmm.09.65.CrossRefPubMed Mattsson N, Zetterberg H: Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications. Biomark Med. 2009, 3: 735-737. 10.2217/bmm.09.65.CrossRefPubMed
63.
go back to reference Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R: A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011, 32: 1090-1098. 10.1016/j.neurobiolaging.2009.06.002.CrossRefPubMed Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R: A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011, 32: 1090-1098. 10.1016/j.neurobiolaging.2009.06.002.CrossRefPubMed
64.
go back to reference Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E: Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides. Neurodegener Dis. 2008, 5: 268-76. 10.1159/000119457.CrossRefPubMed Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E: Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides. Neurodegener Dis. 2008, 5: 268-76. 10.1159/000119457.CrossRefPubMed
65.
go back to reference Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J: The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem. 2008, 54: 1617-23. 10.1373/clinchem.2008.104497.PubMedCentralCrossRefPubMed Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J: The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem. 2008, 54: 1617-23. 10.1373/clinchem.2008.104497.PubMedCentralCrossRefPubMed
66.
go back to reference Sjögren M, Davidsson P, Gottfries J, Vanderstichele H, Edman A, Vanmechelen E: The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord. 2001, 12: 257-64. 10.1159/000051268.CrossRefPubMed Sjögren M, Davidsson P, Gottfries J, Vanderstichele H, Edman A, Vanmechelen E: The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord. 2001, 12: 257-64. 10.1159/000051268.CrossRefPubMed
67.
go back to reference Hesse C, Nilsson CL, Blennow K, Davidsson P: Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis. 2001, 22: 1834-1837. 10.1002/1522-2683(200105)22:9<1834::AID-ELPS1834>3.0.CO;2-V.CrossRefPubMed Hesse C, Nilsson CL, Blennow K, Davidsson P: Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis. 2001, 22: 1834-1837. 10.1002/1522-2683(200105)22:9<1834::AID-ELPS1834>3.0.CO;2-V.CrossRefPubMed
68.
go back to reference Davidsson P, Westman-Brinkmalm A, Nilsson CL, Lindbjer M, Paulson L: Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport. 2002, 13: 611-615. 10.1097/00001756-200204160-00015.CrossRefPubMed Davidsson P, Westman-Brinkmalm A, Nilsson CL, Lindbjer M, Paulson L: Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport. 2002, 13: 611-615. 10.1097/00001756-200204160-00015.CrossRefPubMed
69.
go back to reference Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P: Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res. 2003, 118: 140-146.CrossRefPubMed Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P: Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res. 2003, 118: 140-146.CrossRefPubMed
70.
go back to reference Korolainen MA, Nyman TA, Nyyssönen P, Hartikainen ES, Pirttilä T: Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin Chem. 2007, 53: 657-65. 10.1373/clinchem.2006.078014.CrossRefPubMed Korolainen MA, Nyman TA, Nyyssönen P, Hartikainen ES, Pirttilä T: Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin Chem. 2007, 53: 657-65. 10.1373/clinchem.2006.078014.CrossRefPubMed
71.
go back to reference Sihlbom C, Davidsson P, Sjögren M, Wahlund LO, Nilsson CL: Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochem Res. 2008, 33: 1332-40. 10.1007/s11064-008-9588-x.CrossRefPubMed Sihlbom C, Davidsson P, Sjögren M, Wahlund LO, Nilsson CL: Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochem Res. 2008, 33: 1332-40. 10.1007/s11064-008-9588-x.CrossRefPubMed
72.
go back to reference Zetterberg H, Rüetschi U, Portelius E, Brinkmalm G, Andreasson U, Blennow K, Brinkmalm A: Clinical proteomics in neurodegenerative disorders. Acta Neurol Scand. 2008, 118: 1-11.CrossRefPubMed Zetterberg H, Rüetschi U, Portelius E, Brinkmalm G, Andreasson U, Blennow K, Brinkmalm A: Clinical proteomics in neurodegenerative disorders. Acta Neurol Scand. 2008, 118: 1-11.CrossRefPubMed
73.
go back to reference Vuletic S, Li G, Peskind ER, Kennedy H, Marcovina SM, Leverenz JB: Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid. J Alzheimers Dis. 2008, 15: 409-17.PubMedCentralPubMed Vuletic S, Li G, Peskind ER, Kennedy H, Marcovina SM, Leverenz JB: Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid. J Alzheimers Dis. 2008, 15: 409-17.PubMedCentralPubMed
74.
go back to reference Montine TJ, Quinn J, Kaye J, Morrow JD: F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J Mol Neurosci. 2007, 33: 114-119. 10.1007/s12031-007-0044-1.CrossRefPubMed Montine TJ, Quinn J, Kaye J, Morrow JD: F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J Mol Neurosci. 2007, 33: 114-119. 10.1007/s12031-007-0044-1.CrossRefPubMed
75.
go back to reference Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P: In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid β-peptide of APP. Free Radic Biol Med. 2010, 48: 136-144. 10.1016/j.freeradbiomed.2009.10.035.PubMedCentralCrossRefPubMed Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P: In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid β-peptide of APP. Free Radic Biol Med. 2010, 48: 136-144. 10.1016/j.freeradbiomed.2009.10.035.PubMedCentralCrossRefPubMed
76.
go back to reference Tarkowski E, Blennow K, Wallin A, Tarkowski A: Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol. 1999, 19: 223-230. 10.1023/A:1020568013953.CrossRefPubMed Tarkowski E, Blennow K, Wallin A, Tarkowski A: Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol. 1999, 19: 223-230. 10.1023/A:1020568013953.CrossRefPubMed
77.
go back to reference Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H: Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord. 2006, 21: 9-15. 10.1159/000089137.CrossRefPubMed Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H: Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord. 2006, 21: 9-15. 10.1159/000089137.CrossRefPubMed
78.
go back to reference Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E: Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2006, 63: 538-43. 10.1001/archneur.63.4.538.CrossRefPubMed Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E: Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2006, 63: 538-43. 10.1001/archneur.63.4.538.CrossRefPubMed
79.
go back to reference Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillán C: Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol. 2003, 60: 1218-1222. 10.1001/archneur.60.9.1218.CrossRefPubMed Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillán C: Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol. 2003, 60: 1218-1222. 10.1001/archneur.60.9.1218.CrossRefPubMed
80.
go back to reference Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P: Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol Sci. 2006, 27: 33-39. 10.1007/s10072-006-0562-6.CrossRefPubMed Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P: Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol Sci. 2006, 27: 33-39. 10.1007/s10072-006-0562-6.CrossRefPubMed
81.
go back to reference Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE: Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One. 2011, 6: e16032-10.1371/journal.pone.0016032.PubMedCentralCrossRefPubMed Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE: Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One. 2011, 6: e16032-10.1371/journal.pone.0016032.PubMedCentralCrossRefPubMed
82.
go back to reference De-Paula VJ, Schaeffer EL, Talib LL, Gattaz WF, Forlenza OV: Inhibition of phospholipase A2 increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. Prostaglandins Leukot Essent Fatty Acids. 2010, 82: 57-60. 10.1016/j.plefa.2009.07.006.CrossRefPubMed De-Paula VJ, Schaeffer EL, Talib LL, Gattaz WF, Forlenza OV: Inhibition of phospholipase A2 increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. Prostaglandins Leukot Essent Fatty Acids. 2010, 82: 57-60. 10.1016/j.plefa.2009.07.006.CrossRefPubMed
83.
go back to reference Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA: High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun. 1999, 257: 787-91. 10.1006/bbrc.1999.0552.CrossRefPubMed Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA: High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun. 1999, 257: 787-91. 10.1006/bbrc.1999.0552.CrossRefPubMed
84.
go back to reference Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C: Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging. 2002, 23 (4): 485-508. 10.1016/S0197-4580(01)00328-1.CrossRefPubMed Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C: Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging. 2002, 23 (4): 485-508. 10.1016/S0197-4580(01)00328-1.CrossRefPubMed
85.
go back to reference Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology. 2007, 68: 1902-8. 10.1212/01.wnl.0000263217.36439.da.CrossRefPubMed Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology. 2007, 68: 1902-8. 10.1212/01.wnl.0000263217.36439.da.CrossRefPubMed
86.
go back to reference Teunissen CE, Scheltens P: Use of proteomic approaches to identify disease biomarkers. Lancet Neurol. 2007, 6 (12): 1036-7. 10.1016/S1474-4422(07)70276-4.CrossRefPubMed Teunissen CE, Scheltens P: Use of proteomic approaches to identify disease biomarkers. Lancet Neurol. 2007, 6 (12): 1036-7. 10.1016/S1474-4422(07)70276-4.CrossRefPubMed
87.
go back to reference Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR: Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology. 2004, 62: 1869-71.CrossRefPubMed Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR: Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology. 2004, 62: 1869-71.CrossRefPubMed
88.
go back to reference Anstey KJ, Lipnicki DM, Low LF: Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008, 16: 343-54.CrossRefPubMed Anstey KJ, Lipnicki DM, Low LF: Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008, 16: 343-54.CrossRefPubMed
89.
go back to reference Hochstrasser T, Weiss E, Marksteiner J, Humpel C: Soluble cell adhesion molecules in monocytes of Alzheimer's disease and mild cognitive impairment. Exp Gerontol. 2010, 45: 70-74. 10.1016/j.exger.2009.10.005.PubMedCentralCrossRefPubMed Hochstrasser T, Weiss E, Marksteiner J, Humpel C: Soluble cell adhesion molecules in monocytes of Alzheimer's disease and mild cognitive impairment. Exp Gerontol. 2010, 45: 70-74. 10.1016/j.exger.2009.10.005.PubMedCentralCrossRefPubMed
90.
go back to reference Ewers M, Mielke MM, Hampel H: Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol. 2010, 45: 75-79. 10.1016/j.exger.2009.09.005.PubMedCentralCrossRefPubMed Ewers M, Mielke MM, Hampel H: Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol. 2010, 45: 75-79. 10.1016/j.exger.2009.09.005.PubMedCentralCrossRefPubMed
91.
go back to reference Sun MK, Hongpaisan J, Alkon DL: Postischemic PKC activation rescues retrograde and anterograde long-term memory. Proc Natl Acad Sci USA. 2009, 106: 14676-80. 10.1073/pnas.0907842106.PubMedCentralCrossRefPubMed Sun MK, Hongpaisan J, Alkon DL: Postischemic PKC activation rescues retrograde and anterograde long-term memory. Proc Natl Acad Sci USA. 2009, 106: 14676-80. 10.1073/pnas.0907842106.PubMedCentralCrossRefPubMed
92.
go back to reference de Barry J, Liégeois CM, Janoshazi A: Protein kinase C as a peripheral biomarker for Alzheimer's disease. Exp Gerontol. 2010, 45: 64-69. 10.1016/j.exger.2009.10.015.CrossRefPubMed de Barry J, Liégeois CM, Janoshazi A: Protein kinase C as a peripheral biomarker for Alzheimer's disease. Exp Gerontol. 2010, 45: 64-69. 10.1016/j.exger.2009.10.015.CrossRefPubMed
93.
go back to reference Isagawa T, Mukai H, Oishi K, Taniguchi T, Hasegawa H, Kawamata T: Dual effects of PKNalpha and protein kinase C on phosphorylation of tau protein by glycogen synthase kinase-3beta. Biochem Biophys Res Commun. 2000, 273: 209-12. 10.1006/bbrc.2000.2926.CrossRefPubMed Isagawa T, Mukai H, Oishi K, Taniguchi T, Hasegawa H, Kawamata T: Dual effects of PKNalpha and protein kinase C on phosphorylation of tau protein by glycogen synthase kinase-3beta. Biochem Biophys Res Commun. 2000, 273: 209-12. 10.1006/bbrc.2000.2926.CrossRefPubMed
94.
go back to reference Korolainen MA, Nyman TA, Aittokallio T, Pirttilä T: An update on clinical proteomics in Alzheimer's research. J Neurochem. 2010, 112: 1386-414. 10.1111/j.1471-4159.2009.06558.x.CrossRefPubMed Korolainen MA, Nyman TA, Aittokallio T, Pirttilä T: An update on clinical proteomics in Alzheimer's research. J Neurochem. 2010, 112: 1386-414. 10.1111/j.1471-4159.2009.06558.x.CrossRefPubMed
Metadata
Title
The "Alzheimer's disease signature": potential perspectives for novel biomarkers
Authors
Sergio Davinelli
Mariano Intrieri
Claudio Russo
Alfonso Di Costanzo
Davide Zella
Paolo Bosco
Giovanni Scapagnini
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Immunity & Ageing / Issue 1/2011
Electronic ISSN: 1742-4933
DOI
https://doi.org/10.1186/1742-4933-8-7

Other articles of this Issue 1/2011

Immunity & Ageing 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.